(GILD) Gilead Sciences - Ratings and Ratios

Gilead Sciences, Inc. is a biopharmaceutical company specializing in the discovery, development, and commercialization of innovative medicines for unmet medical needs. The company operates globally, addressing critical therapeutic areas such as HIV/AIDS, COVID-19, viral hepatitis, oncology, pulmonary arterial hypertension, and invasive fungal infections. Its product portfolio includes key HIV therapies like Biktarvy, Genvoya, and Truvada, as well as Veklury for COVID-19 treatment and Epclusa for hepatitis C. The company also markets Yescarta and Tecartus for oncology and Letairis for pulmonary arterial hypertension. Gilead has established strategic collaborations with multiple partners, including Arcus Biosciences, Merck, and Galapagos, to advance its pipeline and expand its therapeutic reach. Incorporated in 1987, the company is headquartered in Foster City, California.

Gileads collaboration agreements with entities like Merus N.V., Terray Therapeutics, and LEO Pharma underscore its commitment to innovation in areas such as trispecific antibodies, small molecule therapies, and STAT6 programs. These partnerships reflect the companys strategic focus on leveraging external expertise to enhance its R&D capabilities and accelerate drug development. Gileads extensive pipeline and collaborative approach position it as a leader in addressing complex and debilitating diseases.

Based on the provided data, Gileads stock (NASDAQ:GILD) is trading at $104.54 with a 20-day average volume of 8,503,950. The stock is below its 20-day SMA of $107.47 and 50-day SMA of $108.15 but above its 200-day SMA of $89.65, indicating short-term consolidation after a significant rally. The ATR of 3.32 suggests moderate volatility. Fundamentally, Gileads market cap stands at $133.7 billion, with a trailing P/E of 282.24 and a forward P/E of 13.59, signaling high current valuations but potential undervaluation in forward estimates. The P/B ratio of 6.92 and P/S of 4.65 highlight a premium valuation relative to book value and sales.

3-Month Forecast: Gileads stock is likely to face resistance near $108-110, given its proximity to the 50-day SMA. Support is expected at $100, aligning with the recent price action. The high trailing P/E may lead to profit-taking, but the forward P/E suggests optimism about future earnings. Collaborative agreements and pipeline advancements could act as catalysts for upside, while macroeconomic factors and competition in the biopharma sector may weigh on performance.